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Abstract
Background: The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a
suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay
characteristics and the performance of the DASL 502-gene Cancer Panel
v1 (1.5K) and 24,526-gene panel (24K)
platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-
negative (HER2-) paraffin-embedded breast tumors.
Methods: Bland-Altman plots and Spearman correlations evaluated intra/inter-panel agreement of normalized
expression values. Unequal-variance t-statistics tested for differences in expression levels between HER2 + and
HER2 - tumors. Regulatory network analysis was performed using Metacore (GeneGo Inc., St. Joseph, MI).
Results: Technical replicate correlations ranged between 0.815-0.956 and 0.986-0.997 for the 1.5K and 24K panels,
respectively. Inter-panel correlations of expression values for the common 498 genes across the two panels ranged
between 0.485-0.573. Inter-panel correlations of expression values of 17 probes with base-pair sequence matches
between the 1.5K and 24K panels ranged between 0.652-0.899. In both panels, erythroblastic leukemia viral
oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors
and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and
HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene
homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein
7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5). The top 52
discriminating probes from the 24K panel are enriched with genes belonging to the regulatory networks centered
around v-myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein p53 (TP53), and estrogen receptor
a (ESR1). Network analysis with a two-step extension also showed that the eight discriminating genes common to
the 1.5K and 24K panels are functionally linked together through MYC, TP53, and ESR1.
Conclusions: The relative RNA abundance obtained from two highly differing density gene panels are correlated
with eight common genes differentiating HER2 + and HER2 - breast tumors. Network analyses demonstrated
biological consistency between the 1.5K and 24K gene panels.
* Correspondence: reinholz.monica@mayo.edu
1Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St
SW, Rochester, Minnesota, 55905, USA
Full list of author information is available at the end of the article
Reinholz et al. BMC Medical Genomics 2010, 3:60
http://www.biomedcentral.com/1755-8794/3/60
© 2010 Reinholz et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
Gene expression profiling is a rapidly advancing field
and has become a useful tool in clinical oncology to
identify molecular differences and similarities that can
be correlated with clinical behavior and drug responsive-
ness. Numerous genes are controlled by complex regula-
tory networks and are involved in the development and
progression of breast cancer, and these genes are the
key factors in determining each characteristic of the
tumor [1,2]. The resulting gene signatures may then
help define cancer subtypes, predict recurrence of dis-
ease and response to specific therapies, and be used to
analyze oncogenic pathways [3]. Microarray studies in
breast cancer research have demonstrated extensive
molecular heterogeneity of breast cancer, identifying dis-
tinct tumor classifications not evident based on tradi-
tional histopathological methods [4,5]. Molecular
phenotyping also has produced gene signatures that may
help predict risk of recurrence in early-stage breast can-
cer patients including several commercially available
panels, Mammaprint (Agendia, Amsterdam, Nether-
lands), OncoType Dx (Genomic Health, Redwood City,
CA), and THEROS H/I (HOXB13:IL17BR; bioTheranos-
tics, San Diego, CA) [6-9].
Formalin-fixed, paraffin-embedded (FFPE) tumor sam-
ples are routinely used for clinical diagnostic purposes
and are the most widely available materials for which
patient outcomes are known. However, many microar-
ray-based analyses use intact ribonucleic acid (RNA)
from fresh frozen tissue, not a commonly available
source of tissue. Thus, FFPE tissue is an invaluable
resource for cancer research, particularly for phase III
adjuvant clinical trials. These large clinical sample sets
are critical for validating molecular profiles of tumor
classification, treatment response, and clinical outcome
prediction. Although RNA isolated from FFPE is usually
highly degraded posing several challenges for microarray
based gene-expression profiling, a reverse transcriptase/
polymerase chain reaction (RT-PCR)-based microarray
technology has been developed to allow high-throughput
profiling of paraffin block tissue samples [10-15].
The complementary DNA-mediated Annealing, exten-
sion, Selection and Ligation (DASL®) assay (Illumina;
San Diego, CA) is a gene expression profiling system
suitable for use with degraded RNAs such as those
derived from FFPE tumor samples [10-18]. The DASL
assay resembles RT-PCR and is designed to target small
cDNA sequences spanning only 50 bases. This is espe-
cially useful for RNA extracted from FFPE tissues as
RNA transcripts are typically less than 200 nucleotides
in length. The DASL assay monitors gene expression in
parallel in archival samples using a minimal amount of
total RNA (~200 ng total RNA per assay). Comparable
results in sensitivity, reproducibility, and accuracy have
been observed between FFPE and snap-frozen tissue of
t h es a m et u m o rw h e nt h eD A S La s s a yi sp e r f o r m e d
according to the pre-analytic quality control criteria
[10-15]. The 502 Cancer Panel
v1 (1.5K) and the whole
genome panel (WG; 24,526 probes; 24K) are DASL
based, commercially available (Illumina, San Diego, CA),
and designed specifically for use with FFPE tissue.
The primary objective of this study was to examine
the performance of the 1.5K and 24K DASL gene panels
to determine whether genes behave similarly between
gene panels with differing densities. The primary techni-
cal objectives were to evaluate the 1) intra-panel agree-
ment of normalized expression values for technical
replicates, 2) intra-panel agreement of normalized
expression values for repeated extracts, 3) inter-panel
agreement of normalized expression values for the 17
probes from the 1.5K panel that had an exact base-pair
sequence match with a sequence internal to a 24K
probe and 4) inter-panel agreement of normalized
expression values for the 498 genes in common between
the two panels. Secondary analyses included biological
objectives evaluating the differential gene expression
patterns between human epidermal growth factor recep-
tor 2-positive (HER2+) and HER2-negative (HER2-)
breast tumors and pathway networks of the highly dis-
criminating genes obtained from the two panels.
Methods
Specimens
This study was approved by the Mayo Clinic Institu-
tional Review Board and performed in accordance with
institutional and federal guidelines. Informed consent
was documented. Twenty archived FFPE breast tumor
specimens (procured between 1998 and 2006) were
obtained from the Mayo Clinic Tissue Registry, Roche-
ster, MN and were frequently matched on estrogen and
progesterone receptor, tumor size, nodal status, and
subject age (Table 1). The majority of the tumors were
procured before routine and standardized HER2 testing
(e.g., HercepTest; Dako, Carpinteria, CA) [19] thus, dif-
ferent immunohistochemical staining techniques were
used to determine the HER2 status of the breast tumors
in the Tissue Registry, and a HER2 immunohistochemis-
try (IHC) score of 3+ was defined as > 10% of cells with
complete membrane staining according to Food and
Drug Administration (FDA)-approved guidelines [20]
(Table 1, initial HER2 score). As there have been
changes in pathologic interpretation of HER2 expression
over time [19], we performed the HercepTest on a fresh
cut FFPE tissue section from each specimen according
to manufacturer’s instructions (Dako). This clinical vari-
able was defined as the HercepTest HER2 score (Table
1), and an IHC score of 3+ was defined as > 30% of
cells with complete membrane staining according to the
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Page 2 of 16Table 1 Clinicopathological characteristics of 20 breast tumors
Characteristic Total N = 20 % HER2+ N = 9 (%) HER2- N = 11 (%)
Median age (range) 58.5 (35, 76) 57 (35, 73) 59 (38, 76)
Age Group:
< 40 3 15 2 (22) 1 (9)
40-49 2 10 1 (11) 1 (9)
50-59 6 30 2 (22) 4 (36)
≥ 60 9 45 4 (44) 5 (46)
Initial HER2 Status:
06 3 0
1 + 1 5 NA NA
2+ 0 0
3 + 13 65
Hercept Test HER2 Status:
04 2 0
1+ 7 3 5 N A N A
2+ 2 1 0
3+ 7 3 5
Estrogen Status:
Positive 20 100 9 (100) 11 (100)
30% ER+ cells 0 (0) 0 (9)
70% ER+ cells 1 (11) 0 (0)
80% ER+ cells 2 (22) 1 (9)
90% ER+ cells 2 (22) 4 (36)
95% ER+ cells 2 (22) 2 (18)
100% ER+ cells 2 (22) 2 (18)
% cell not recorded 0 (0) 0 (0)
Negative 0 0
Progesterone Status:
Positive 19 95 9 (100) 10 (91)
Negative 1 5 0 (0) 1 (9)
Nodes Positive:
1-3 10 50 5 (56) 5 (46)
4-9 6 30 2 (22) 4 (36)
≥ 10 4 20 2 (22) 2 (18)
Predominant Tumor Histology:
Ductal 20 100 9 (100) 11 (100)
Lobular 0
Nottingham Grade:
2 11 55 4 (44) 8 (73)
3 9 45 5 (56) 3 (27)
Stage:
2 12 60 5 (56) 7 (64)
3 8 40 4 (44) 4 (36)
Pathologic Tumor Size:
< 2 cm 5 25 3 (33) 2 (18)
≥ 2 cm 15 75 6 (67) 9 (82)
Year of Block Procurement:
1998-2000 3 15 22 (22) 1 (9)
2001-2003 11 55 4 (44) 7 (64)
2004-2006 6 30 3 (33) 3 (27)
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American Pathology (ASCO/CAP) guidelines [19]. Two
pathologists (B.C.; A.E.M.) reviewed the HER2 staining
of the tumors on whole sections (B.C.) and tissue micro-
array sections (A.E.M.) and were 100% concordant,
except in the two cases that were re-classified as 2+; the
whole section score was 2+ and the average TMA score
was 1+. An additional case was classified as 3+ upon
initial and central review but the average TMA score
was 2+. For HER2 expression level comparisons, tumors
with 2+ or 3+ IHC staining patterns in whole sections
were considered HER2+ (n = 9) and tumors with 0 or 1
+ staining patterns were considered HER2- (n = 11). Of
the 20 tumors, 80% (16/20) of the tissues had ≥ 80%
invasive tumor component. The clinicopathological
characteristics of the 20 tumors are shown in Table 1.
RNA Extraction
Total RNA was extracted from six 5 μm thick whole tis-
sue sections from each sample using the Roche Hi-Pure
RNA Extraction kit according to manufacturer’s instruc-
tions (Roche, Indianapolis, IN). The concentration of
the purified RNA was determined using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies;
Wilmington, DE). Purified total RNA samples were
stored frozen at -80°C until needed for quality control
(QC) analysis and subsequent gene expression profiling.
The average RNA yield was 5.4 ± 2.5 μg (range: 2.6-
12.6) with an average 260:280 ratio of 2.08 ± 0.05
(range: 1.99-2.22). Representative Agilent tracings
demonstrated that the majority of the RNA transcripts
were ~ 200 bp in length (data not shown). Replicate
extractions were performed for eight of the twenty
breast tumors. Additionally, technical replicates were
performed on eight tumor specimens including four of
the extract replicate samples.
1.5K and 24K Gene Panels
Two Illumina human gene panels with partially overlap-
ping probe content were used for the array hybridization
experiments. The 502-gene Cancer Panel
v1 (1.5K) has
1506 probes associated with 502 unique gene symbols
[21]. The whole-genome 24,526 probe (24K) panel [16]
was developed based on content derived from the
National Center for Biotechnology Information Refer-
ence Sequence [NCBI RefSeq Database (Build 36.2,
Release 22)]. The 24K has 24,526 probes associated with
18,401 gene symbols. The 1.5K panel has 3 probes
representing each gene and the 24K platform has one to
eight probes representing a particular gene.
The 498 genes in common between the two panels
were determined by matching the gene symbol, gene
symbol alias, Reference Sequence (RefSeq) Accession
Number, and/or the Entrez Gene ID. Probes from 466
genes were matched by exact gene symbol matches.
Probes from an additional 27 genes were matched by
their RefSeq Accession Number. Probes from five genes
were matched based on gene symbol aliases, Entrez
Gene identification numbers, and alternative RefSeq
Accession Number. The data discussed in this publica-
tion have been deposited in NCBI’s Gene Expression
Omnibus [22] and are accessible through GEO Series
accession number GSE25234 http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE25234.
RNA Labeling and Hybridizations
For the 1.5K DASL multiplex experiments, labeling and
hybridizations were performed as previously described
[11-13] in the Mayo Clinic Genotyping Shared Resource
(Rochester, MN). Briefly, 200 ng total RNA was con-
verted to complementary deoxyribonucleic acid (cDNA)
using biotinylated oligo-dT18 and random nonamer pri-
mers, followed by immobilization to a streptavidin-
coated solid support. Pre-qualification of cDNA (1 μl)
was assessed by quantitative RT-PCR analysis of the
housekeeping gene, RPL13a, following the Illumina
recommended qPCR. The range of observed Cq values
was 19.75-33.34. The biotinylated cDNAs were then
annealed to assay-specific oligonucleotides creating PCR
templates that were amplified using fluorescently-labeled
and biotinylated universal primers. The labeled PCR
products were then captured on streptavidin paramag-
netic beads, washed and denatured to yield single-
stranded fluorescent molecules which were hybridized,
via short ~22 nucleotide sequences, to a Sentrix Univer-
sal-96 Array Matrix (SAM) for 16 hr using a 60°C to 45°
C temperature gradient. For the 24K experiment, the
procedure was essentially similar to that described for
the 1.5K DASL experiments, the difference being that
the assay-specific oligonucleotide designs varied such
that the hybridizations were performed via 50 nucleotide
sequences to whole-genome gene expression BeadChips
(HumanRef-8 v3 Beadchip, Illumina) for 16 hr at 58°C.
The 24K experiment was performed at Illumina using
aliquots of the same RNA used in the 1.5K experiment.
For both the 1.5K and 24K chips the fluorescence inten-
sities were read on BeadArray Readers.
Analysis of Array Image Data
The probe intensity values were extracted from the
images by the GenomeScanner Software within BeadAr-
ray Readers. The Gene Expression module from Illu-
mina BeadStudio analysis software was used to process
the intensity data and provide a preliminary analysis and
measures of quality control. Each oligonucleotide probe
is represented, on average, by 30 beads per hybridized
sample. BeadStudio summarizes the pixel intensities for
each bead and then averages over the redundant beads
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number of control oligonucleotide probes are spiked
into the hybridization mix to estimate image intensity
due to non-specific binding and target binding specifi-
city. Universal Human Reference RNA (UHRR) samples
(Agilent Technologies, Santa Clara, CA) comprised from
10 human cell lines were used as control RNA samples
to assess the quality of RNA labeling and hybridization
in each DASL assay. The UHRR was selected as one of
the two standards in the FDA led Microarray Quality
Control (MAQC) project [23]. Inter-plate controls were
also included to assess reproducibility between plates.
For the 24K data, all samples passed array quality con-
trol, having robust signal intensities (> 700 counts),
good sensitivity (~14000 probes per sample detected
(p < 0.01) and having good reproducibility for expres-
sion profiles across technical replicates (average
r
2~0.98). For both platforms, the annealing and hybridi-
zation controls performed well, indicating that both the
DAP annealing (sample-dependent) and array hybridiza-
tion (sample-independent) components of the assay per-
formed well. In addition, no significant associations (at
p < 0.05 level) were observed between the year the
block was procured and RPL13a qPCR Cq values or the
scanner P95 readings (Additional File 1, Figures S1-S2).
Statistical Analysis
The non-background corrected expression values were
exported from BeadStudio and normalized using fastlo
[24], a model-based, intensity-dependent normalization
method that produces results essentially the same as
those from cyclic loess [25]. Intra- and inter-panel
agreement of normalized base-2 logarithm-transformed
expression values was evaluated using Bland-Altman
plots and Spearman correlations. A Bland-Altman plot
is a plot of the difference between two measurements
(A - B) against the average of the two measurements
(A + B)/2. In comparison to a simple correlation plot of
A versus B, a Bland-Altman plot provides a better visua-
lization of the magnitude of disagreement (error and
bias) and better highlights outliers and trends in the dis-
agreement. If the differences between two measurements
are not related to the magnitude of either measurement,
then it is expected that the data will be randomly scat-
tered around the zero horizontal reference line. A local
regression line is included on the Bland-Altman plot to
visualize trends in the data. Unequal-variance t-statistics
were utilized from the first extract and first replicate
(for patients with technical and/or extract replicates) to
test for differences in expression levels between HER2+
and HER2- patients at the probe level. Probes with a p-
value < 0.01 and log2-fold change > |1.0| were classified
as candidates for being differentially expressed. Next,
expression data were summarized for each of the 498
genes in common between the 1.5K and 24K panels by
averaging the base-2 logarithm-transformed normalized
expression values for all probes that match to a particu-
lar gene symbol on the corresponding panel. Unequal-
variance t-statistics were utilized to test for differences
in expression levels between HER2+ and HER2- patients
at the gene level; genes with a p-value < 0.05 and log2-
fold change > |0.5| were classified as candidates for
being differentially expressed. The proportion fold
change agreement was analyzed by calculating the pro-
portion of genes that had the same fold change direc-
tion; for example, the fold change for a specific gene
would be considered in agreement if the fold change
values from the 1.5K and 24K were both either positive
or negative. All analyses were conducted using the soft-
ware R [26].
Network Analysis
Network analyses were performed using MetaCore net-
work building tools (GeneGo Inc., St. Joseph, MI). The
Dijkstra’s shortest paths algorithm [27]) was used to
find the shortest directed paths between the genes
allowing two steps in the path. We used the curated
interactions only between genes from MetaCore data-
base of interactions. In order to investigate the func-
tional relationships between the top discriminating
genes from the 24K panel, probes having p-values
< 0.01 and log2-fold change > |1.0| between HER2+ and
HER2- tumors were selected for network analysis based
on the pair-wise regulatory relationships annotated by
MetaCore. Network analysis was also performed on the
eight genes that were differentially expressed between
HER2+ and HER2- tumors (p-value < 0.05 and log2-fold
change > |0.5|) common to both the 1.5K and 24K
panels.
Results
Inter-panel agreement across the 1.5K and 24K Gene
Panels
The Pearson correlations associated with technical repli-
cates ranged from 0.815 to 0.956 for the 1.5K panel and
0.986 to 0.997 for the 24K panel for the 498 genes in
common across the panels. Figures 1a and 1b show
Bland-Altman plots comparing the agreement of nor-
malized gene expression intensities across a set of tech-
nical replicates associated with a single representative
t i s s u es a m p l ef o rt h e1 . 5K( 1a) and 24K (1b)p a n e l s .
For the tissue sample displayed in Figure 1, the variabil-
ity associated with technical replicates is larger for the
1 . 5Kp a n e li nc o m p a r i s o nt ot h e2 4 Kp a n e l ;t h es t a n -
dard deviation associated with the difference in expres-
sion between the set of technical replicates shown is
0.551 for the 1.5K panel and 0.214 for the 24K panel.
The Pearson correlations associated with extract
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a. c.
b. d.
      
e. 
Figure 1 Bland-Altman plots displaying intra-panel agreement of technical and extract replicates. a. Technical-replicate agreement of
normalized expression for the 1.5K panel. b. Technical-replicate agreement of normalized expression for the 24K panel. c. Extract-replicate
agreement of normalized expression for the 1.5K. d. Extract-replicate agreement of normalized expression for the 24K panel. The vertical axis
denotes the difference in expression values between the technical replicates and the horizontal axis denotes the average expression for each of
the 498 genes in common. A local regression line is superimposed on figures a-d. e. Summarized standard deviations of the differences for each
of the eight samples with technical replicates and eight samples with extract replicates.
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and 0.988 to 0.997 for the 24K panel for the 498 genes
in common. Figures 1c and 1d show Bland-Altman
plots comparing the agreement of normalized gene
expression intensities across extract replicates associated
w i t has i n g l er e p r e s e n t a t i v es u b j e c t .F o rt h es u b j e c td i s -
played, the variability associated with extract replicates
is larger for the 1.5K panel in comparison to the 24K
panel; the standard deviation associated with the differ-
ence in expression between extract replicates for the
same tumor sample is 0.69 for the 1.5K panel and 0.214
for the 24K panel. Figure 1e summarizes the standard
deviation associated with the difference in expression
across technical replicates for all 8 tissue samples that
had technical replicates performed. The standard devia-
tion for technical replicates was notably smaller for the
24K panel indicating that the 24K panel produces more
precise expression values. Figure 1e also summarizes the
standard deviation associated with the difference in
expression across extract replicates. The standard devia-
tion for extract replicates was again notably smaller for
the 24K panel indicating that the 24K panel produces
more precise expression values. Note that four samples
had both technical replicates and replicate extracts and
these samples are connected with horizontal lines.
Figure 2a is a Bland-Altman plot displaying the inter-
panel agreement of the normalized expression values for
the 17 sequence-matched probes associated with a single
representative tissue sample. Similarly, Figure 2b pro-
vides a Bland-Altman plot with a local regression line
for each of the 20 samples that were hybridized on both
gene panels. In general, the local regression lines are
above the zero horizontal reference line indicating that
the 1.5K panel produced larger expression values than
the 24K panel. More strikingly, the difference in expres-
sion was attenuated for probes expressed at a low level.
The Pearson correlations associated with the 17
sequenced-matched probes between the 1.5K and 24K
a.  c.
b. d.
Figure 2 Bland-Altman plots displaying inter-panel agreement of common probes. a. Inter-panel agreement for the 17 sequence-matched
probes for a single representative sample, with a local regression line superimposed. b. A local regression line representing each of the 20
samples. c. Inter-panel agreement for the 498 gene symbols in common across the 1.5K and 24K panels for a single sample, with a local
regression line superimposed. d. A local regression line for each of the 20 samples.
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ples. Figures 2c and 2d show Bland-Altman plots dis-
playing the agreement of the normalized expression
values for the 498 genes in common across the two plat-
forms. Again, the 1.5K panel generally produced larger
expression values than the 24K panel and the difference
in expression was attenuated for genes expressed at a
low level. The Pearson correlations associated with the
498 common genes between the 1.5K and 24K panels
ranged from 0.485 to 0.573 across the 20 samples.
HER2 expression
Three probes on the 1.5K panel represent erythroblastic
leukemia viral oncogene homolog 2 (ERBB2; HER2):
GI.4758297.S.1789, GI.4758297.S.1787, and GI.4758297.
S.1786. Similarly, three probes on the 24K panel repre-
sent ERBB2: ILMN_1717902, ILMN_1728761, and
ILMN_ 2352131. Figure 3 displays the normalized
expression for the ERBB2 probes for both panels; probes
are plotted in the order of 5-prime, middle, and 3-prime
end of the gene. For both panels, ERBB2 gene expres-
sion was significantly lower in HER2- than in HER2+
samples for all three probes on both panels (p < 0.003
for all probes). The normalized expression across probes
was more variable within the 24K panel compared to
the 1.5K panel.
At the gene level, larger correlations between the 1.5K
and 24K panels were observed for genes that were
represented by more probes. For the 498 genes in com-
mon across the two platforms, the 1.5K panel had 3
probes representing each gene. However, the 24K panel
had 333 genes that were represented by a single probe,
86 that were represented by two probes, 64 that were
represented by three probes, and 15 that were repre-
sented by four-six probes. The average expression was
calculated for each platform for all 498 genes in com-
mon. The median correlation of expression levels across
t h eg e n ep a n e l sw e r e0 . 3 6( 1
st/3
rd quartiles: 0.1843/
0.5990), 0.46 (1
st/3
rd quartiles: 0.2404/0.6517), 0.49 (1
st/
3
rd quartiles: 0.2323/0.6893), and 0.53 (1
st/3
rd quartiles:
0.3915/0.6102) for genes having one, two, three, and
four to six probes per gene on the 24K panel, respec-
tively (Additional File 1, Figure S3).
Fold change agreement of genes differentiating HER2+ vs
HER2- tumors
In addition to comparing normalized expression values
across the two panels, we also evaluated the agreement
a.  DASL 1.5K ERBB2 Expression 
     Expression Per Case: All Replicates 
b.  DASL 24K ERBB2 Expression 
     Expression Per Case: All Replicates 
Figure 3 ERBB2 gene expression. a. ERBB2 (HER2) expression for the three probes on the 1.5K panel. b. ERBB2 (HER2) expression for the three
probes on the 24K panel. From left to right the three probes are ordered from the 5-prime to 3-prime end of ERBB2. The ERBB2 probe positions
for the 1.5K panel are: 607 for GI.4758297.S.1789-5prime; 1192 for GI.4758297.S.1787-middle; and 4106 for GI.4758297.S.1786-3prime. The ERBB2
probe positions for the 24K panel are: 47 for ILMN_1717902-5prime; 370 for ILMN1728761-middle; and 4390 for ILMN_2352131-3prime. Internal
to each probe the samples are sorted by HER2 IHC 0-3+ values. Open circles represent tumors with HerceptTest IHC scores of 0-1+ and closed
triangles represent tumors with HerceptTest IHC scores of 2-3+.
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HER2- expression at the gene level (Figure 4). To
determine agreement, the fold change values were
dichotomized as follows: a gene was classified as up-
regulated if the log2 fold change was larger than zero
and down-regulated if the log2 fold change was less
than zero. The two panels agreed if both panels called
a gene up-regulated or both panels called a gene down
r e g u l a t e d .A sg e n e st h a ta r ee x p r e s s e da tv e r yl o w
levels are usually below the noise threshold and thus,
will be randomly classified as up- or down-regulated, it
is more appropriate to evaluate agreement among the
genes that are expressed above a noise level. To obtain
a more accurate estimate of agreement, Figure 4a pro-
vides the proportion of concordant calls using a range
of noise thresholds. For example, using a noise thresh-
old of zero (i.e., no threshold), the agreement across
all 498 common genes was 63% (314/498). The agree-
ment improved to 68% (196/289) and 85% (64/75)
when considering only the set of genes that had a log2
fold change (noise threshold) > |0.2| and |0.5| in at
least one of the panels, respectively. Figure 4b displays
the agreement of expression values using a noise
threshold of |0.2|, i.e. considering only genes that pro-
duced a log2 fold change larger than |0.2| in at least
one of the panels. There were 289 genes where at least
one of the panels had a log2 fold change greater than |
0.2|; the direction of the fold change was concordant
for 97 up-regulated and 99 down-regulated genes and
discordant for 93 genes.
Table 2 indicates that the ERBB2 gene was the most
differentially expressed gene for both panels (p <
0.0001). Seven additional genes had p-values < 0.05 and
log2-fold change > |0.5| gene expression change
between HER2+ and HER2- tumors in both panels:
topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-
fos fbj murine osteosarcoma viral oncogene homolog
(FOS), wingless-type mmtv integration site family, mem-
ber 5a (WNT5A), growth factor receptor-bound protein 7
(GRB7), cell division cycle 2 (CDC2), and baculoviral
iap repeat-containing protein 5 (BIRC5). An additional
14 and 17 genes from the 1.5K and 24K panels, respec-
tively, had log2-foldchange > |0.5| and p-values < 0.05;
Table 2 provides the log2-fold change and p-values for
both panels for these discordant genes.
Network Analyses
Table 3 lists the top 52 discriminating probes (repre-
senting 47 genes) from the 24K panel having p-values <
0.01 and log2-fold change > |1.0| between HER2+ and
HER2- tumors. Network analysis of the 47 genes
showed that several of these genes (indicated by red cir-
cles) are functionally linked to v-myc avian myelocyto-
matosis viral oncogene homolog (MYC), tumor protein
p53 (TP53), and estrogen receptor a (ESR1)( F i g u r e5 A -
B). The top five discriminating genes from the 24K
a. b.
Figure 4 Fold change agreement of genes differentiating HER2+ versus HER2- tumors. a. Agreement of fold change estimates for the 1.5K
and 24K panels for a range of noise thresholds. b. Agreement of fold change using a noise threshold of |0.20|, i.e., considering only genes that
have a log2-fold change large than |0.20| in at least one of the panels.
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protein 1 (PERLD1), anti-silencing function 1, s. cerevi-
siae, homolog B (ASF1B), and chromosome 17 open read-
ing frame 37 (C17ORF37). Network analyses showed
that the top eight discriminating genes common to both
panels (indicated by red circles) are connected in a net-
work built by the shortest path algorithm allowing two
steps in the path (Figure 5C). The hubs of the networks
include MYC, TP53, and ESR1.
Table 2 Genes that had a log2-fold change > |0.5| and a
t-test p-value < 0.05
DASL 1.5K DASL 24K
Symbol p-value log2-fold change p-value log2-fold change
ERBB2 0.00002 1.560 0.00001 1.522
TOP2A 0.00238 0.820 0.02047 1.260
CCNA2 0.00275 0.880 0.03336 0.572
FOS 0.01719 -0.834 0.01814 -0.848
WNT5A 0.01779 -0.697 0.01086 -0.873
GRB7 0.01802 0.816 0.00027 1.924
CDC2 0.02282 0.588 0.00946 0.886
BIRC5 0.03098 0.721 0.04624 0.738
MST1R 0.00142 -0.855 0.18625 -0.715
CTSL1 0.00504 0.565 0.46187 0.173
KLF6 0.00629 -0.530 0.62433 0.078
VAV2 0.00873 -0.612 0.98142 0.005
ELK3 0.00877 -0.541 0.31326 -0.161
AREG 0.01172 1.089 0.04873 0.227
RASA1 0.01268 0.831 0.70107 -0.048
LIG4 0.01291 -0.526 0.66921 0.078
XRCC2 0.01457 0.622 0.02547 0.307
RAD52 0.01908 -0.530 0.60233 -0.117
IGF2 0.02324 -0.748 0.02119 -0.477
TFAP2C 0.03411 0.633 0.01484 0.339
TYMS 0.04853 0.582 0.06550 0.582
TNFSF10 0.04884 0.533 0.06095 0.562
CDKN2D 0.33534 0.190 0.00431 0.501
IGFBP6 0.05152 -0.289 0.00447 -0.627
BCL6 0.00786 -0.417 0.00866 -0.520
CCNE1 0.86111 0.036 0.01106 0.629
BMP4 0.06932 -0.786 0.01395 -0.815
PTCH1 0.64341 -0.122 0.01807 -0.589
PBX1 0.13206 0.276 0.01853 0.550
EGR1 0.09200 -0.232 0.01887 -0.646
RAB8A 0.88338 -0.027 0.02049 0.603
BLM 0.24745 0.355 0.02160 0.875
MYCN 0.45713 0.262 0.02168 1.213
MPL 0.00606 -0.460 0.02810 -0.551
TGFB2 0.29992 -0.332 0.03025 -0.979
RAD54L 0.94663 0.013 0.03996 0.642
MAP3K8 0.73556 -0.050 0.04151 0.683
CDC25C 0.47633 0.197 0.04316 0.728
HMMR 0.12330 0.502 0.04816 0.779
Note: Italicized values do not pass the p-value or fold change threshold.
Table 3 Probes from the 24K panel that had a log2-fold
change > |1.0| and a t-test p-value < 0.01
Symbol p-value log2-fold change
ERBB2* 0.0000001 1.458
ERBB2* 0.00004 2.017
GRB7 0.00008 1.851
C17ORF37 0.00009 1.131
PERLD1 0.00011 1.966
GRB7 0.00028 1.817
ASF1B 0.00041 1.306
PAPSS2 0.00057 1.257
GRB7 0.00091 2.119
C13ORF3 0.00095 1.073
CDC6 0.00099 1.756
MND1 0.00119 1.178
C5ORF4 0.00123 -1.203
DUSP15 0.00167 -1.456
FAM54A 0.00178 1.223
ERBB2* 0.00179 1.063
PSMD3* 0.00184 1.087
KCND3 0.00199 -1.359
PLEKHB1 0.00204 -1.133
ITIH4 0.00207 -1.062
SMARCD3 (BAF60C)* 0.00234 -1.122
LOC441376 0.00259 -1.966
PLP1 0.00297 -1.440
GLT25D2* 0.00301 -1.074
MAPT 0.00325 -1.352
CA2 (carbonic anhydrase II)* 0.00341 -1.446
CCNE1 0.00367 1.189
VAX2 0.00389 -1.229
TXLNB* 0.00395 -1.088
NUSAP1 0.00409 1.141
OSTALPHA 0.00420 2.421
IGFN1 0.00435 -1.251
CEP55 0.00448 1.211
DIAPH3* 0.00473 1.052
CCDC48 0.00521 -1.445
CCDC153 0.00551 -1.048
PMP2 0.00551 -1.185
MGC20983 0.00579 -1.247
AURKB* 0.00595 1.025
FLJ25770 0.00624 -1.259
EXO1* 0.00626 1.042
HYDIN 0.00643 -1.318
DTL* 0.00676 1.251
ATP6V0A4 0.00787 1.940
S100A7* 0.00787 3.327
ARTN 0.00824 -1.379
EME1 (MMS4L)* 0.00842 1.021
SPAG6* 0.00853 -2.443
POLQ (DNA polymerase kappa) * 0.00882 1.090
ROBO2 0.00941 -1.679
PLP1 0.00946 -1.190
ZNF695 0.01000 1.414
*Genes that cluster around MYC, P53,a n dESR1 and indicated by red circles in
Figure 5 a-b.
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Gene expression profiling has created new possibilities
for the molecular characterization of cancer. The result-
ing gene expression signatures have the potential to
explain the genetic heterogeneity of breast cancer and
allow treatment strategies to be planned in accordance
with their probability of success in individual patients
[2]. Molecular classification is changing the design of
clinical trials. For example, the TAILORx http://www.
cancer.gov/clinicaltrials/digestpage/TAILORx[28] and
MINDACT http://www.eortc.be/services/unit/mindact/
MINDACT_websiteii.asp[29] are two adjuvant breast
cancer treatment trials in which patients are stratified
according to select gene signatures present in their
excised breast tumor. The molecular differences that
underlie the phenotypes of breast cancer could reveal
new therapeutic targets and influence clinical care [30].
To optimize the full capability of gene expression profil-
ing using microarray-based assays, technologies are being
optimized to reliably perform gene expression profiling on
FFPE specimens, currently the most common type of clini-
cal specimen available, particularly for phase III adjuvant
treatment trials. FFPE is an extremely valuable resource of
tissue for discovery and validation studies. While the com-
bination of the Affymetrix GeneChip® Human X3P Array
(Santa Clara, Ca) and Arcturus Paradise™ system (Moun-
tain View, CA) has been optimized for FFPE tissue, it has
been the experience of other investigators [31] and our-
selves (unpublished observations) that call rates are unac-
ceptably low, typically less than 30% [31]. Whereas, we
observed high call rates (percent of detectable genes at the
p = 0.01 level), which are sample dependent, on average of
> 87% and > 75% from the 1.5K and 24K panels, respec-
tively (data not shown). Almac (Belfast, Ireland) has
 
b. 24K panel p53/ESR1 cluster. 
d. Symbol legend. 
a. 24K panel c-Myc cluster. 
c. Top eight genes common to both panels.  
Figure 5 MetaCore network analyses. The top 47 genes that matched to the probes that were differentially expressed between HER2+ and
HER2- samples (p-values < 0.01 and log2-fold change > |1.0|) in the 24K panel are enriched with genes (marked by red cycles) belonging to
two distinct regulatory networks. a. The first network includes genes (marked by red cycles) functionally connected to MYC (c-Myc). b. The
second network is enriched by genes (marked by red cycles) centered around TP53 (p53) and ESR1. c. The 8 genes differentially expressed in
both the 24K and 1.5K panels (marked by red cycles) are all connected in a network that includes TP53 (p53), ESR1, and MYC (c-Myc) d. Symbol
legend. Abbreviations for gene names presented in Figure 5 are defined in Additional File 1, Tables S1-S3.
Reinholz et al. BMC Medical Genomics 2010, 3:60
http://www.biomedcentral.com/1755-8794/3/60
Page 11 of 16developed a promising technology that utilizes Affymetrix-
based methodology and disease-specific arrays (DSAs) or
transcriptome panels that have ~ 50,000 transcripts that
can be utilized for FFPE tissue [32,33].
The present report describes gene expression analyses
of FFPE using the DASL Assay from Illumina, designed
specifically to profile degraded RNAs derived from FFPE
tumor samples. The DASL Assay has a dynamic range
of 2.5 to 3 logs and limit of detection of 1 × 10
4 mole-
cules, parameters comparable to those determined using
standard microarray molecular profiling [13]. Custom
and commercially available gene panels have been suc-
cessfully used on the DASL platform and resulting gene
signatures have proven to have diagnostic value. A cus-
tom 512-gene panel was used to identify gene signatures
that correlated with Gleason score and relapse of pros-
tate cancer [34]. The 502 Cancer Panel
v1 and a 526 cus-
tom gene panel were used to identify gene expression
patterns that were significantly associated with systemic
progression after prostate specific antigen recurrence in
men with prostate cancer [21]. The whole genome 24K
gene panel for use with the DASL platform recently
became commercially available [16].
Our objective was to compare the performance of the
1.5K panel to the more recent 24K panel using the
DASL platform to determine whether genes behave
similarly between gene panels with different densities.
The high correlations (0.815-0.997) observed between
technical and extract replicates for both gene panels
demonstrate that the reproducibility of results from
both the 1.5K and 24K gene panels was excellent. The
24K panel revealed less variation between both technical
and extract replicates compared to the 1.5K panel.
A l t h o u g hi tm a yb ee x p e c t e dt h a tt h ev a r i a b i l i t yo f
hybridization signal intensities would be less for the
1.5K panel due to the higher probe density per gene for
the 1.5K compared to the 24K panel, the 24K panel has
a more stringent array hybridization condition compared
to the 1.5K panel (i.e., the length of the probes is 50
nucleotides for the 24K BeadArray compared to ~22
nucleotides for the 1.5K panel). In addition, most of the
genes on the 1.5K array are cancer-related and thus, in
our study were expressed at higher levels compared to
the genes on the 24K array. Furthermore, the intensity
for the 1.5K array is the sum of a dual color assay (cy3
+cy5 channels), whereas the 24K assay is a single-color
assay (cy3), the hybridization conditions and washes are
different, and the readouts are different (Universal Array
Matrix versus whole genome BeadChip) and therefore,
the scan settings are different. Lastly, it should be recog-
nized that these technologies measure relative expres-
sion within the context of each platform.
As only 17 probes are identical of the 498 common
genes, the two platforms have mostly non-overlapping
nucleotide sequences for the same transcript target. The
targeted regions in the 24K assay were designed to cor-
respond to the largely 3’ biased 50 nucleotide probe
sequence content of the HumanRef-8 v3 BeadChip [16]
and the targeted regions of the 1.5K assay were not
restricted to the 3’ end of transcripts [13]. Specific
probe information can be found online at http://www.
switchtoi.com/annotationfiles.ilmn[35]. For genes with
poor fold-change correlations, it is also conceivable that
the probes may be identifying splice variants of the
same gene, and thereby targeting different mRNA iso-
forms due to variations in probe position on the panels.
At the gene level, we observed larger median correla-
t i o n sb e t w e e nt h e1 . 5 Ka n d2 4 Kp a n e l sf o rg e n e st h a t
were represented by more probes. In addition, within-
platform data for the 1.5K assay, the expression profiles
generated with three probes/transcript correlated well
(R
2~0.99) with those profiles generated with four or
more (up to ten) probes/transcript [13].
The inter-panel agreementw a sg o o df o rp r o b e sw i t h
sequences that matched across the 1.5K and 24K panels;
correlations ranged from 0.652 to 0.899. However, the
agreement for probes that had different sequences that
mapped to the same gene had fair correlation across the
two panels; correlations ranged from 0.485 to 0.573.
This is not unexpected as the expression level appears
t ob eaf u n c t i o no ft h ep r o b es equence location within
the gene such that different probe sequences may corre-
spond to different cDNA synthesis efficiencies and dif-
ferent oligo hybridization efficiencies [23]. This was
particularly evident for the ERBB2 gene expression
obtained from the 24 K panel (Figure 3). It has been
suggested that the differences in expression values
between the two panels could result from non-specific
h y b r i d i z a t i o ni nt h e1 . 5 Ka r r a y( s i n c ei n c r e a s ei ns t r i n -
gency in the hybridization affects the intensity of expres-
sion values) or from the increased complexity of the
labeling step in the 24 K array that may lead to “less”
labeling and reduced hybridization. However, hybridiza-
tion conditions for both platforms have been optimized
for the different length of probe (~22 vs. 50 nucleotides)
minimizing non-specific/cross-hybridization. Also, the
short address codes for the 1.5K array were carefully
selected to have a similar overall length, GC-content,
and melting temperature (Tm), whereas for the 24K
array the targeted regions were somewhat restrained
having been pre-determined by the 50 nucleotide probe
sequences on the whole-genome gene expression Bead-
Chip (HumanRef-8 v3). Despite the differences in abso-
lute intensity, the relative differences between the HER2
+ and HER2- groups is conserved across both platforms
and all six probes.
It is also important to note that because of differences
between the two platforms [e.g., non-overlapping
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well as different hybridization conditions for the 1.5K
and 24K assays (as described above)], direct compari-
sons of the raw intensities will yield seemingly poor
cross-platform correlations. However, fold-change corre-
lations of the gene intensities between the two platforms
provide a common metric for comparisons.
Both panels detected significant differential ERBB2
gene expression between HER2+ and HER2- breast
tumors, and the HER2 gene was the most differentially
expressed gene for both panels. These results indicate
that both panels correctly classified the HER2 status of
the tumors when comparing gene expression to protein
expression determined by IHC (gold standard) and
when considering IHC score of 0-1+ as HER2- and IHC
scores of 2-3+ as HER2+. The two tumors that had an
IHC score of 2+ as defined by the 2007 ASCO/CAP
guidelines [19] were initially considered 3+ when using
the FDA-approved guidelines [20]. In addition, there
were eight concordant genes across the panels that had
a log2-fold change > |0.5| and p-value < 0.05 to differ-
entiate between HER2+ and HER2- tumors. Two of
these 8 genes, ERBB2 and GRB7,a r ei nt h e1 0 - g e n e
HER2 cluster observed by Perou and Sorlie [4,5]. We
selected tumors to closely match on hormone receptor
(majority are positive) and nodal status (all node posi-
t i v e )t om a x i m i z et h ed i f f e r e n c ei ng e n es i g n a t u r e sl a r -
gely resulting from the HER2 phenotype. We also
wanted to minimize the molecular heterogeneity that
can be found in HER2+ tumors, influenced by the hor-
mone receptor status and basal-type signatures [36,37].
Several well-known gene signatures identifying the same
population of patients have very few genes in common,
a feature of complex gene-expression data that contain
large numbers of highly correlated variables (i.e., gene-
expression measurements) [30]. Several different combi-
nations of the correlated variables can be selected to
build similarly accurate prediction models. Thus, differ-
ent differential gene lists from various platforms can be
considered comparable when they reveal similar biologi-
cal functions [38].
As the main purpose of gene expression studies using
microarrays is to reveal the underlying biological differ-
ences between groups, functional networks were gener-
ated using MetaCore. We observed that the top 52
discriminating probes from the 24K panels are enriched
with genes functionally linked to MYC and TP53/ESR1
networks. Nine of the 10 genes in the HER2 gene cluster
from the Perou/Sorlie dataset [4,5] form a regulatory
network also centered around TP53 and ESR1.I na d d i -
tion, four (ERBB2, GRB7, PERLD1,a n dC17ORF37)o f
the top five HER2 discriminating genes from the 24K
panel are genes commonly amplified in the HER2 ampli-
con (17q12-q21) and were overexpressed in HER2+
tumors. Their gene expressions were also highly corre-
lated (r
2 = 0.806-0.912, p < 0.005). Lastly, network ana-
lyses showed that the top eight discriminating genes
common to both panels are connected by the shortest
path network analysis with a two-step extension. Inter-
connecting genes include c-Myc (MYC), TP53,a n d
ESR1.
Thus, it appears that genes in the MYC, TP53,a n d
ESR1 regulatory networks are important in differentiat-
ing between HER2-positive and -negative tumors. HER2
expression has been shown to be influenced by the pre-
sence of ESR1 [36,37,39-42]. Although we selected
tumors positive for the estrogen receptor protein (ER+)
by immunohistochemistry, 11 of 13 HER2 0-2+ tumors
had high ESR1 expression (≥ 12), whereas only two of
the seven HER2 3+ tumors had high ESR1 expression
(Fisher’s Exact p = 0.022). In addition, significant corre-
lations between ESR1 gene expression and ER protein
expression levels were observed for the 1.5K (r
2 = 0.71;
p = 0.002) and 24K (r
2 = 0.65; p = 0.006) panels (Addi-
tional File 1, Figure S4). Overall, the network analysis
demonstrated biological consistency between the gene
panels. Our data are consistent with recent findings that
demonstrated that highly consistent biological informa-
tion can be generated from different microarray plat-
f o r m s[ 3 8 ] .A st h i ss t u d yw a sd e s i g n e dp r i m a r i l yt o
evaluate and compare the technical performances of the
two platforms with pre-defined tumor selection (e.g., all
ER+ and node-positive tumors), conclusions regarding
clinically relevant information of HER2+/HER2- biology
need to be further validated.
Conclusions
Our results indicate that the relative gene expression
intensities are highly correlated and biological consis-
tency is observed between two different density gene
panels when analyzed using the DASL technology.
These findings suggest that the 1.5K and 24K panels are
both adequate platforms for gene expression profiling of
FFPE tumors. The 24K panel is ideally suited for whole
genome screening/discovery studies, whereas, the 1.5K
panel is suitable for cancer-focused studies. Screening of
the 24K panel is also an appropriate approach to iden-
tify smaller, promising gene signatures, which when vali-
dated, can be utilized in clinical testing.
Our results and previous findings, taken together,
demonstrate that the DASL assay provides a reliable
approach to gene expression profiling in FFPE tumors.
Several reports have already shown that gene signatures
arising from the DASL assay have prognostic potential.
A promising direction of research is to examine the
hypothesis that different markers and biologic pathways
may be involved in determining prognosis, response,
and resistance to therapy in different molecular
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data sets become available for gene-expression analysis,
the DASL assay using FFPE tissue will help develop pre-
dictors of molecular class-specific prognosis and treat-
ment response. This will allow for detailed
investigations of gene pathways and interactions indi-
cated by the resultant gene signatures that are truly pre-
dictive of clinical endpoints to better understand the
biology underlying the disease [43-46]. Lastly, the com-
bination of multiple forms of molecular data (protein-
and gene-based) and clinical and demographic factors
has the potential to identify unique characteristics of the
individual and lead to more effective customized health
care strategies [47,48].
Additional material
Additional file 1: Figures S1-S4 and Tables T1-T3. Additional Figures
S1-S3 are additional figures (S1-S2) that explain the associations between
1) block procurement year and RP13a qPCR Cq, 2) block procurement
year and scanner p95 readings, and 3) RP13a and qPCR Cq and scanner
p95 readings. An additional figure (S3) explains the correlation between
gene panels according to number of probes per 24K gene symbol.
Additional Figure S4 explains the relationship between ER
immunohistochemical staining and ESR1 gene expression intensity.
Additional Tables T1-T3 define the gene symbols presented in Figure 5.
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